PDT Partners LLC Invests $794,000 in Haemonetics Co. (NYSE:HAE)

PDT Partners LLC acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,168 shares of the medical instruments supplier's stock, valued at approximately $794,000.

Several other large investors also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans lifted its holdings in Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after buying an additional 164,111 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Haemonetics by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after purchasing an additional 10,990 shares during the last quarter. Boston Trust Walden Corp boosted its position in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Haemonetics by 0.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock valued at $62,802,000 after purchasing an additional 5,668 shares during the last quarter. Finally, Fisher Asset Management LLC raised its holdings in Haemonetics by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock worth $55,575,000 after purchasing an additional 22,265 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

Shares of Haemonetics stock traded up $1.33 on Tuesday, reaching $63.82. 141,718 shares of the stock were exchanged, compared to its average volume of 859,044. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The business has a 50 day moving average price of $62.69 and a two-hundred day moving average price of $71.59. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the topic of a number of analyst reports. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. StockNews.com upgraded Haemonetics from a "hold" rating to a "buy" rating in a report on Monday. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, Raymond James reiterated a "strong-buy" rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.